Instil Bio, Inc. Debt Securities, Available-for-sale, Amortized Cost
Instil Bio, Inc. (TIL) had Debt Securities, Available-for-sale, Amortized Cost of $77.28 million as of 2025-09-30, per its 10-Q filed 2025-11-13.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2025-11-13
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $77.28M.
- 2025-06-30: Debt Securities, Available-for-sale, Amortized Cost $95.83M.
- 2025-03-31: Debt Securities, Available-for-sale, Amortized Cost $95.47M.
- 2024-09-30: Debt Securities, Available-for-sale, Amortized Cost $116.06M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost |
|---|---|
| 2025-09-30 | $77.28M 10-Q · filed 2025-11-13 |
| 2025-06-30 | $95.83M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $95.47M 10-Q · filed 2025-05-13 |
| 2024-09-30 | $116.06M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $146.00M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $156.12M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $164.21M 10-K · filed 2025-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |